Closing the Gap: Expanding Access to Mifepristone for Early Pregnancy Loss Through Operational Innovation.

ABSTRACT: Management of early pregnancy loss (EPL) with mifepristone plus misoprostol is the evidence-based standard of care endorsed by the American College of Obstetricians and Gynecologists. This 2-drug regimen demonstrates superior outcomes compared to misoprostol alone or expectant management, including fewer complications, higher success rates, and reduced need for surgical intervention. Though mifepristone use for EPL management is legal in all 50 states, it is vastly underutilized in emergency departments (EDs), which see a substantial percentage of patients with EPL. This is partly due to regulations around prescribing and dispensing it that create logistical barriers, especially in unscheduled care settings. Expanded access to mifepristone in the ED has the potential to reduce disparities

SUBMITTER: Rowh MAW 

PROVIDER: S-EPMC12702207 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature